Observational research evaluates cardiovascular implications of performance enhancing drugs in athletes, highlighting ethical concerns.
TEG's potential to provide valuable scientific insights should not be interpreted as a proof-of-concept for safe, extreme-level performance enhancement, but rather as a high-risk observational setting that demands exceptional ethical scrutiny, transparency, and long-term accountability. While ethical and regulatory debates dominate public discourse, TEG also presents a research opportunity to systematically evaluate the CV effects of PED use under controlled conditions. A dedicated, risk-adapted pre-participation screening and longitudinal monitoring framework will be essential for characterizing PED-associated CV effects and informing harm-reduction strategies.
No takes yet. Share an insight, caveat, or question.
Vecchiato et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: